5-Amino-1MQ: research reference

Keep entity and method together: transferring a result between formulations requires evidence even when their names overlap.

NNMT transfers a methyl group from S-adenosylmethionine to nicotinamide. Its inhibition modulates nicotinamide availability in the dinucleotide salvage pathway in cellular models.

The purity value is a product-label specification, not an assay result. A batch result can only be asserted from that batch’s certificate.

These names help identify the catalog entry. A descriptive label is not evidence of efficacy, and structural identity still requires appropriate documentation.

Enzyme inhibitor

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Personal protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

This bibliography covers three research fronts with different methods. Medicinal chemistry on the primary-amine methylquinolinium scaffold began with permeability assays in artificial membranes and Caco-2 monolayers, plus selectivity comparisons against S-adenosylmethionine-dependent methyltransferases and dinucleotide-salvage enzymes. In cultured adipocytes, the work quantified intracellular enzyme-reaction product, dinucleotide and methyl donor, as well as lipogenesis, in vitro.

The metabolic front used a mouse model of high-fat-diet obesity, examining enzyme inhibition alongside replacement with a lean diet. Measurements included body weight, fat mass, lean-mass-to-weight ratio, liver and epididymal white-adipose weights, hepatic steatosis and the adipose-tissue metabolomic signature.

The third front concerns aged mouse skeletal muscle after acute local injury. It followed muscle stem-cell proliferation and fusion, fiber cross-sectional area and size distribution, in vivo contractile function and dinucleotide redox state in C2C12 myoblasts. None is a human trial. The medicinal-chemistry review organizes the mechanism and inhibitor classes. Sources: PMID 29155147; PMID 33707534; PMID 30753815; PMID 34458733.

Peptide-centered exposure concepts—plasma half-life, albumin binding and peptidase cleavage—do not characterize this molecule in its bibliography. Membrane passage is characterized: primary-amine-substituted methylquinolinium analogs showed passive and active transport in artificial membranes and Caco-2 monolayers without inhibiting related methyltransferases or salvage-pathway enzymes in vitro. Cellular entry plus selectivity is the medicinal-chemistry paper’s argument for the scaffold.

For systemic behavior, the translational review lists limited bioavailability, insufficient target engagement and unestablished safety profiles as obstacles for the class. None of this record’s references reports half-life, plasma-protein-bound fraction or elimination route, and none is inferred here. Sources: PMID 29155147; PMID 42067476.

The molecule arose from working backward from a target rather than from clinical observation. Gene-expression analysis of white adipose tissue from mice with adipocyte GLUT4 suppression or overexpression identified the enzyme among reciprocally changing genes. Antisense-oligonucleotide silencing in adipose tissue and liver was then studied in dietary-obesity models, linking the enzyme to polyamine flux, histone methylation and dinucleotide availability.

The chemical series followed target validation: methylquinolinium analogs selected for permeability and selectivity were tested first in adipocytes and then in a high-fat-diet mouse model. The same group later moved the series into aged skeletal-muscle research in rodents. The translational review describes later generations of compounds with high cellular affinity for the enzyme. Sources: PMID 24717514; PMID 29155147; PMID 30753815; PMID 42067476.

A useful catalog comparison concerns structure and target. Other metabolic-category compounds are peptides or fragments described around membrane-receptor biology: HGH Fragment 176-191 appears in adipocyte lipolysis work and GHRH analogs at a G protein-coupled receptor in preclinical literature. 5-Amino-1MQ is a quinolinium salt, not a peptide, and is described at a cytosolic enzyme rather than the cell surface. Its in vitro selectivity is therefore tested against other methyltransferases rather than related receptors.

NAD+, listed as a cellular cofactor, provides another point of contact: NNMT consumes nicotinamide, a precursor of that cofactor, placing the two at opposite ends of the same pathway in cellular models. MOTS-c also concerns energy metabolism but is a mitochondrially encoded peptide sharing neither structure nor target. Experimental suitability depends on the laboratory question, not a ranking. Sources: PMID 29155147; PMID 34458733.

There are no human trials in this record. The translational review leaves target engagement, bioavailability and safety unresolved for the class. Attribution is another limitation: preclinical papers identify the tested substance as an NNMT inhibitor from a chemical series, and published material does not always tie each observation to this specific salt.

The foundational mechanistic chain—polyamine flux, histone methylation and sirtuin-dependent signaling—comes from genetic silencing in animals, not from this molecule. It is not established that a small-molecule inhibitor reproduces that full chain. Metabolic and muscle studies use different models, ages and measurements, without a published direct comparison or independent replication between them. Sources: PMID 42067476; PMID 30753815; PMID 29155147; PMID 24717514.